Safety and efficacy of protease inhibitor based combination therapy in a single-center “real-life” cohort of 110 patients with chronic hepatitis C genotype 1 infection

BACKGROUND: The combination of boceprevir or telaprevir with peginterferon-alfa and ribavirin for the treatment of patients infected with HCV genotype 1 has led to significantly increased rates of sustained virological response (SVR) in phase III trials. There is only limited data regarding the safe...

Deskribapen osoa

Gorde:
Xehetasun bibliografikoak
Egile Nagusiak: Wehmeyer, Malte H, Eißing, Friederike, Jordan, Sabine, Röder, Claudia, Hennigs, Annette, Degen, Olaf, Hüfner, Anja, Hertling, Sandra, Schmiedel, Stefan, Sterneck, Martina, van Lunzen, Jan, Lohse, Ansgar W, zur Wiesch, Julian Schulze, Lüth, Stefan
Formatua: Artigo
Hizkuntza:Inglês
Argitaratua: BioMed Central 2014
Gaiak:
Research Article
Sarrera elektronikoa:https://ncbi.nlm.nih.gov/pmc/articles/PMC4102246/
https://ncbi.nlm.nih.gov/pubmed/24884400
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/1471-230X-14-87
Etiketak: Etiketa erantsi
Etiketarik gabe, Izan zaitez lehena erregistro honi etiketa jartzen!

Antzeko izenburuak